EMT6 - Syngeneic Model
Rincon Bio performs EMT6 syngeneic models to test efficacy of immunotherapies. Please see below for additional information or to request a quote.
EMT6 was established from a transplantable murine mammary carcinoma that arose in a BALB/cCRGL mouse after implantation of a hyperplastic mammary alveolar nodule. The resulting tumor line (named KHJJ) was propagated in BALB/cKa mice and adapted to tissue culture after the 25th animal passage, and the cell line was named EMT. EMT6 is a clonal isolate of EMT isolated in 1971 at Stanford University.
Used as a syngeneic model. Implanted tumor cells create a model in which to test the efficacy of novel immunotherapies
Forms solid tumors in some sublines of BALB/c mice
Rincon Bio Survival Curve
WHY WORK WITH
When you work with Rincon Bio, rest assured that all cancer efficacy studies will be performed in the USA, at competitive prices
Most efficacy studies can be initiated within two business days.
We love our clients! We take a personal interest in our clients and their studies.